These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 34570508)

  • 1. Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-
    Johannes JW; Balazs A; Barratt D; Bista M; Chuba MD; Cosulich S; Critchlow SE; Degorce SL; Di Fruscia P; Edmondson SD; Embrey K; Fawell S; Ghosh A; Gill SJ; Gunnarsson A; Hande SM; Heightman TD; Hemsley P; Illuzzi G; Lane J; Larner C; Leo E; Liu L; Madin A; Martin S; McWilliams L; O'Connor MJ; Orme JP; Pachl F; Packer MJ; Pei X; Pike A; Schimpl M; She H; Staniszewska AD; Talbot V; Underwood E; Varnes JG; Xue L; Yao T; Zhang K; Zhang AX; Zheng X
    J Med Chem; 2021 Oct; 64(19):14498-14512. PubMed ID: 34570508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper.
    Illuzzi G; Staniszewska AD; Gill SJ; Pike A; McWilliams L; Critchlow SE; Cronin A; Fawell S; Hawthorne G; Jamal K; Johannes J; Leonard E; Macdonald R; Maglennon G; Nikkilä J; O'Connor MJ; Smith A; Southgate H; Wilson J; Yates J; Cosulich S; Leo E
    Clin Cancer Res; 2022 Nov; 28(21):4724-4736. PubMed ID: 35929986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305.
    Zheng J; Li Z; Min W
    Front Pharmacol; 2022; 13():979873. PubMed ID: 36756144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin.
    Dellavedova G; Decio A; Formenti L; Albertella MR; Wilson J; Staniszewska AD; Leo E; Giavazzi R; Ghilardi C; Bani MR
    Cancer Res Commun; 2023 Mar; 3(3):489-500. PubMed ID: 36994441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Single-Molecule Atomic Force Microscopy Study of PARP1 and PARP2 Recognition of Base Excision Repair DNA Intermediates.
    Sukhanova MV; Hamon L; Kutuzov MM; Joshi V; Abrakhi S; Dobra I; Curmi PA; Pastre D; Lavrik OI
    J Mol Biol; 2019 Jul; 431(15):2655-2673. PubMed ID: 31129062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting PARP2 and PARP1 trapping through quantitative live-cell imaging.
    Zhang H; Lin X; Zha S
    Biochem Soc Trans; 2022 Aug; 50(4):1169-1177. PubMed ID: 35959996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B; Ye N; Song SS; Wang YT; Song Z; Chen HD; Chen CH; Huan XJ; Wang YQ; Su Y; Shen YY; Sun YM; Yang XY; Chen Y; Guo SY; Gan Y; Gao ZW; Chen XY; Ding J; He JX; Zhang A; Miao ZH
    Cancer Lett; 2017 Feb; 386():47-56. PubMed ID: 27847302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serine-linked PARP1 auto-modification controls PARP inhibitor response.
    Prokhorova E; Zobel F; Smith R; Zentout S; Gibbs-Seymour I; Schützenhofer K; Peters A; Groslambert J; Zorzini V; Agnew T; Brognard J; Nielsen ML; Ahel D; Huet S; Suskiewicz MJ; Ahel I
    Nat Commun; 2021 Jul; 12(1):4055. PubMed ID: 34210965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel inhibitors of poly(ADP-ribose) polymerase/PARP1 and PARP2 identified using a cell-based screen in yeast.
    Perkins E; Sun D; Nguyen A; Tulac S; Francesco M; Tavana H; Nguyen H; Tugendreich S; Barthmaier P; Couto J; Yeh E; Thode S; Jarnagin K; Jain A; Morgans D; Melese T
    Cancer Res; 2001 May; 61(10):4175-83. PubMed ID: 11358842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic inhibitor selectivity between PARP1 and PARP2 enzymes: Molecular implications for ovarian cancer personalized therapy.
    Zuo X; Zhao H; Li D
    J Mol Recognit; 2021 Jul; 34(7):e2891. PubMed ID: 33684965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly (ADP-ribose) polymerases inhibitor, Zj6413, as a potential therapeutic agent against breast cancer.
    Zhou Q; Ji M; Zhou J; Jin J; Xue N; Chen J; Xu B; Chen X
    Biochem Pharmacol; 2016 May; 107():29-40. PubMed ID: 26920250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and in vitro biological evaluation of 3-ethyl-1,5-naphthyridin-2(1H)-one derivatives as potent PARP-1 selective inhibitors and PARP-1 DNA trappers.
    Ren J; Quan X; Liu Y; Li J; Zhang X; Li Z; Zhang X
    Bioorg Med Chem Lett; 2022 Dec; 78():129046. PubMed ID: 36343904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicinal chemistry approaches of poly ADP-Ribose polymerase 1 (PARP1) inhibitors as anticancer agents - A recent update.
    Jain PG; Patel BD
    Eur J Med Chem; 2019 Mar; 165():198-215. PubMed ID: 30684797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dynamics and regulation of PARP1 and PARP2 in response to DNA damage and during replication.
    Zhang H; Zha S
    DNA Repair (Amst); 2024 Aug; 140():103690. PubMed ID: 38823186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Oncogenic Helicase ALC1 Regulates PARP Inhibitor Potency by Trapping PARP2 at DNA Breaks.
    Blessing C; Mandemaker IK; Gonzalez-Leal C; Preisser J; Schomburg A; Ladurner AG
    Mol Cell; 2020 Dec; 80(5):862-875.e6. PubMed ID: 33275888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
    Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
    J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. XRCC1 prevents toxic PARP1 trapping during DNA base excision repair.
    Demin AA; Hirota K; Tsuda M; Adamowicz M; Hailstone R; Brazina J; Gittens W; Kalasova I; Shao Z; Zha S; Sasanuma H; Hanzlikova H; Takeda S; Caldecott KW
    Mol Cell; 2021 Jul; 81(14):3018-3030.e5. PubMed ID: 34102106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitotic functions of poly(ADP-ribose) polymerases.
    Slade D
    Biochem Pharmacol; 2019 Sep; 167():33-43. PubMed ID: 30910692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP trapping is governed by the PARP inhibitor dissociation rate constant.
    Gopal AA; Fernandez B; Delano J; Weissleder R; Dubach JM
    Cell Chem Biol; 2024 Jul; 31(7):1373-1382.e10. PubMed ID: 38262416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leveraging shape screening and molecular dynamics simulations to optimize PARP1-Specific chemo/radio-potentiators for antitumor drug design.
    Khizer H; Maryam A; Ansari A; Ahmad MS; Khalid RR
    Arch Biochem Biophys; 2024 Jun; 756():110010. PubMed ID: 38642632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.